All In Biotech

Drug Trial Radar · NCT00044291

Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer

Last checked: Nov 20, 2026Latest source record: Jul 31, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 865 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

865

Actual

Start

Jun 2002

Primary completion

Jan 2006

Study completion Jan 2006

Sponsor

Lead sponsor
Intarcia TherapeuticsIndustry
Sponsor type
Industry
First posted
Aug 27, 2002

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether the first line combination hormonal therapy of an experimental drug, atamestane, plus an FDA-approved drug, toremifene (Fareston®), is more effective than another approved drug, letrozole (Femara®), in delaying the growth of breast cancer in postmenopausal patients with locally advanced or metastatic breast cancer, and whether the side effects of the combination are different from the side effects of letrozole.

Conditions

  • Breast Neoplasms
  • Neoplasms, Hormone-dependent

Interventions

  • atamestaneDrug

  • toremifeneDrug

  • letrozoleDrug

  • aromatase inhibitionDrug

  • hormone therapyProcedure

  • endocrine therapyProcedure

  • antiestrogen therapyProcedure

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to tumor progressionTime frame: time from randomization to first occurrence of tumor progression, assessed at week 12 and every subsequent 12 weeks for patients continuing in the study for up to approximately 36 months

Locations

63 sites in 4 countries. Site status is shown where the registry gives one.

  • Midwest Internal Medicine, PLLC

    Lake Havasu City, Arizona

  • Arizona Clinical Research Center

    Tucson, Arizona

  • California Cancer Care, Inc.

    Greenbrae, California

  • Sharp Memorial Hospital

    San Diego, California

  • Innovative Medical Research of South Florida Inc.

    Miami Shores, Florida

  • Georgia Cancer Specialists

    Tucker, Georgia

  • Maryland Hematology/Oncology Associates

    Baltimore, Maryland

  • Oncology Care Associates, PLLC

    Saint Joseph, Michigan

  • Kansas City Oncology and Hematology Group

    Kansas City, Missouri

  • Great Falls Clinic-Oncology West

    Great Falls, Montana

  • Slocum-Dickson Medical Group

    New Hartford, New York

  • Hematology Oncology Consultants, Inc.

    Columbus, Ohio

  • Oncology Consultants

    Houston, Texas

  • First Dynamic Healthcare Services, Inc.

    Killeen, Texas

  • Cache Valley Cancer Treatment & Research Clinic

    Logan, Utah

  • Virginia Oncology Associates

    Norfolk, Virginia

  • Western Washington Oncology Inc., P.S.

    Olympia, Washington

  • Ottawa Regional Cancer Centre

    Ottawa, Ontario, Canada

  • Northwestern Ontario Regional Cancer Centre

    Thunder Bay, Ontario, Canada

  • Princess Margaret Hospital

    Toronto, Ontario, Canada

  • McGill University, Department of Oncology

    Montreal, Quebec, Canada

  • Arkhangelsk Regional Oncology Center, Department of Chemotherapy

    Arkhangelsk, Russia

  • Tatarstan Republican Clinical Oncology Center

    Kazan', Russia

  • Krasnodar Regional Clinical Oncology Center, Chemotherapy Department

    Krasnodar, Russia

  • Lipetsk Regional Oncology Center, Department of General Oncology

    Lipetsk, Russia

  • Blokhin Cancer Research Center, Department of Chemotherapy and Combined Treatment of Tumors

    Moscow, Russia

  • Blokhin Cancer Research Center, Department of Chemotherapy

    Moscow, Russia

  • Blokhin Cancer Research Center, Department of Clinical Pharmacology and Chemotherapy

    Moscow, Russia

  • Blokhin Cancer Research Center, Department of New Antitumor Drug Research

    Moscow, Russia

  • Hertzen Research Institute of Oncology, Department of Chemotherapy

    Moscow, Russia

  • Central Clinical Hospital of the Ministry of Transport n.a. Semashko, Department of Chemotherapy

    Moscow, Russia

  • Moscow City Hospital #40, Department of Chemotherapy

    Moscow, Russia

  • Moscow City Oncology Hospital #62

    Moscow, Russia

  • Murmansk Regional Oncology Center

    Murmansk, Russia

  • Municipal Clinical Hospital #1, Department of Breast Tumors, Oncology Department

    Novosibirsk, Russia

  • Medical Radiological Research Center

    Obninsk, Russia

  • Ryazan Regional Clinical Oncology Center

    Ryazan, Russia

  • Leningrad Regional Oncology Center

    Saint Petersburg, Russia

  • St. Petersburg City Oncology Center

    Saint Petersburg, Russia

  • Laboratory of Thoracic Oncology, St. Petersburg Pavlov State Medical University, Research Institute of Pulmonology

    Saint Petersburg, Russia

Showing 40 of 63 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.